Table 1.
Current status of clinical trials of treatment of alopecia areata with JAK inhibitors listed on clinicaltrials.gov.
| Trial Listing | Identifier | Molecule | Recruiting | Location | Study Type | AA type | Start Date |
|---|---|---|---|---|---|---|---|
| A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata | NCT03354637 | Topical JAK inhibitor | Yes | Multicenter | Phase 2; RCT with Placebo; 120 Subjects | Moderate to severe (SALT 30-95%) | Nov 28, 2017 |
| Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) | NCT03315689 | Topical JAK inhibitor | Yes | Multicenter | Phase 2; RCT with Placebo; 12 Subjects | Moderate to severe (AT/AU) | Oct 20, 2017 |
| Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | NCT03137381 | Oral JAK inhibitor | Yes | Multicenter | Phase 2; RCT with Placebo; 90 Subjects | Moderate to severe | May 2, 2017 |
| Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata | NCT02974868 | Oral JAK inhibitor | Active, not recruiting | Multicenter | Phase 2; RCT with Placebo; 143 Subjects | Moderate to severe | Nov 29, 2016 |
| Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants | NCT02812342 | Oral Tofacitinib | Active, not recruiting | Yale University | Phase 2; Open label; 10 Subjects | Moderate to severe (>50% SALT to AT/AU) | June 24, 2016 |
| Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis | NCT02299297 | Oral Tofacitinib | Active, not recruiting | Columbia University | Phase 2; Open label; 15 Subjects | Moderate to severe (AT/AU) | Nov 24, 2014 |
| LEO 124249 Ointment in the Treatment of Alopecia Areata | NCT02561585 | Topical JAK inhibitor | Completed | Icahn/Mount Sinai and North Western University | Phase 2; RCT with Placebo; 31 Subjects | Moderate to severe (SALT >30%, AT/AU) | Sept 28, 2015 |
| Tofacitinib for the Treatment of Alopecia Areata and Its Variants | NCT02312882 | Oral Tofacitinib | Completed | Stanford University | Phase 2; Open label; 40 Subjects | Moderate to severe (>50% SALT to AT/AU) | Dec 9, 2014 |
| Tofacitnib for the Treatment of Alopecia Areata and Variants | NCT02197455 | Oral Tofacitinib | Completed | Yale University | Phase 2; Open label; 30 Subjects | Moderate to severe (>50% SALT to AT/AU) | July 22, 2014 |
| Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata | NCT01950780 | Oral Ruxolitinib | Completed | Columbia University | Phase 2; Open label; 12 Subjects | Moderate to severe (SALT 30-95%) | Sept 25, 2013 |
| A Study With INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) | NCT02553330 | Topical Ruxolitinib | Terminated | Multicenter | Phase 2; RCT with Placebo; 90 Subjects | Partial or complete AA | Sept 17, 2015 |